These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9066045)

  • 41. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
    Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
    Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes.
    Hitri K; Kuttel MM; De Benedetto G; Lockyer K; Gao F; Hansal P; Rudd TR; Beamish E; Rijpkema S; Ravenscroft N; Bolgiano B
    Vaccine; 2019 Jun; 37(29):3866-3875. PubMed ID: 31160100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
    Yang HH; Wu CG; Xie GZ; Gu QW; Wang BR; Wang LY; Wang HF; Ding ZS; Yang Y; Tan WS; Wang WY; Wang XC; Qin M; Wang JH; Tang HA; Jiang XM; Li YH; Wang ML; Zhang SL; Li GL
    Bull World Health Organ; 2001; 79(7):625-31. PubMed ID: 11477965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
    Pakkanen SH; Kantele JM; Rombo L; Kantele A
    Scand J Immunol; 2017 Oct; 86(4):207-215. PubMed ID: 28675263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
    N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Vi polysaccharide vaccine against Salmonella typhi.
    Arya SC
    Vaccine; 1999 Mar; 17(9-10):1015-6. PubMed ID: 10195609
    [No Abstract]   [Full Text] [Related]  

  • 49. Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines.
    Gibani MM
    Lancet Infect Dis; 2022 Apr; 22(4):435-436. PubMed ID: 34942089
    [No Abstract]   [Full Text] [Related]  

  • 50. A single shot at Salmonella typhi: a new typhoid vaccine with pediatric advantages.
    Hall CB
    Pediatrics; 1995 Aug; 96(2 Pt 1):348-50. PubMed ID: 7630698
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
    Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
    Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity.
    Parker AR; Bradley C; Harding S; Sánchez-Ramón S; Jolles S; Kiani-Alikhan S
    J Immunol Methods; 2018 Aug; 459():1-10. PubMed ID: 29800575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial.
    Blok BA; Arts RJW; van Crevel R; Aaby P; Joosten LAB; Benn CS; Netea MG
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1177-1184. PubMed ID: 32065303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with Salmonella typhi Vi capsular polysaccharide vaccine.
    Hessel L; Debois H; Fletcher M; Dumas R
    Eur J Clin Microbiol Infect Dis; 1999 Sep; 18(9):609-20. PubMed ID: 10534182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Crump JA; Oo WT
    Lancet; 2021 Aug; 398(10301):643-644. PubMed ID: 34384541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.